Novare Capital Management LLC Buys 1,492 Shares of Johnson & Johnson $JNJ

Novare Capital Management LLC increased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 121,485 shares of the company’s stock after buying an additional 1,492 shares during the quarter. Johnson & Johnson accounts for 1.5% of Novare Capital Management LLC’s investment portfolio, making the stock its 17th largest holding. Novare Capital Management LLC’s holdings in Johnson & Johnson were worth $18,557,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also bought and sold shares of the company. Apexium Financial LP grew its holdings in Johnson & Johnson by 10.7% during the first quarter. Apexium Financial LP now owns 23,989 shares of the company’s stock worth $3,978,000 after buying an additional 2,310 shares in the last quarter. Avanza Fonder AB boosted its position in Johnson & Johnson by 2.9% in the second quarter. Avanza Fonder AB now owns 234,647 shares of the company’s stock worth $35,842,000 after purchasing an additional 6,566 shares during the last quarter. Joel Isaacson & Co. LLC boosted its position in Johnson & Johnson by 3.5% in the first quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company’s stock worth $12,294,000 after purchasing an additional 2,526 shares during the last quarter. Tokio Marine Asset Management Co. Ltd. boosted its position in Johnson & Johnson by 7.0% in the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 73,350 shares of the company’s stock worth $12,164,000 after purchasing an additional 4,816 shares during the last quarter. Finally, Absher Wealth Management LLC boosted its position in Johnson & Johnson by 1.2% in the first quarter. Absher Wealth Management LLC now owns 215,584 shares of the company’s stock worth $35,752,000 after purchasing an additional 2,469 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

JNJ has been the topic of several research analyst reports. Raymond James Financial boosted their price objective on Johnson & Johnson from $174.00 to $209.00 and gave the stock an “outperform” rating in a research report on Wednesday. Stifel Nicolaus boosted their price objective on Johnson & Johnson from $165.00 to $190.00 and gave the stock a “hold” rating in a research report on Wednesday. Wall Street Zen raised Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Saturday, September 13th. JPMorgan Chase & Co. upped their price target on Johnson & Johnson from $185.00 to $200.00 and gave the company a “neutral” rating in a research report on Tuesday, September 16th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and set a $209.00 price target on shares of Johnson & Johnson in a research report on Friday, October 10th. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $199.88.

Johnson & Johnson Stock Up 0.6%

Shares of NYSE JNJ opened at $193.27 on Monday. Johnson & Johnson has a one year low of $140.68 and a one year high of $194.40. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The business’s fifty day moving average price is $180.49 and its 200-day moving average price is $164.90. The stock has a market capitalization of $465.45 billion, a PE ratio of 18.65, a P/E/G ratio of 2.27 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson & Johnson had a return on equity of 33.08% and a net margin of 27.26%. On average, equities research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be issued a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. Johnson & Johnson’s dividend payout ratio is 50.19%.

Insider Transactions at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.